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This guidance is intended for providers of drug treatment services across all tiers. It is essential that
efficiently functioning integrated care pathways are in place to ensure that the interface between tiers of
treatment is as seamless as possible.
Drug taking is inherently risky. The actual level of risk involved in drug use is, of course, highly variable
and dependent on factors such as the physiology of the person taking the drug, the type of drug used
and the method of use. It is impossible to remove all risk from all drug use, but it is essential that drug
treatment services work closely with individuals who are engaging in high-risk drug-taking behaviours. 
Treatment services need to be attractive and accessible to drug users, while attempting to minimise the
risks involved in their drug use.
Even services with the best and most comprehensive drug treatment provision will inevitably encounter
clients who die as a direct result of their drug use. Services should have the aim of reducing drug-
related deaths (particularly among drug users at high risk), rather than strategies that fail to engage
effectively with high-risk users.
Recent concern has focused on the increasing numbers of deaths among drug users, many of which
are preventable. The Advisory Council on the Misuse of Drugs report, Reducing Drug-Related Deaths
(ACMD 2000), established the broad nature and scope of the problem and made suggestions for
improvements both in the planning and delivery of services to drug users and in the collection of data.
This briefing paper sets out various strategies for reducing drug-related deaths from both short-term
causes such as overdose and long-term causes such as diseases caused by the transmission of
blood-borne viruses. It includes basic guidance and is not intended to be a prescriptive template, nor to
stifle innovation. Models of Care for Substance Misuse Treatment (NTA 2002) gives guidance on the
organisation and planning of treatment services and the establishment of integrated care pathways to
ensure an effective drug treatment system. Models of Care should be extensively referred to in
conjunction with this guidance.
Key target
The Department of Health Action Plan 2001 set a target, which has been included in the Updated
Drugs Strategy 2002, of a 20% reduction in drug-related deaths by March 2004 – working from a
national baseline set in 1999 of 1568 deaths.
Many drug-related deaths are easily preventable, others are less so, but a 20% reduction would
represent around 300 lives saved nationally over one year and is an achievable target. However, it is
likely that increased attention to drug-related deaths will lead to better reporting, initially causing the
drug-related death rate to appear to rise.
The number of immediate drug-related deaths can be more easily measured than those resulting from
long-term causes, which may occur decades after the drug use. However, the transmission of blood-
borne viruses and illness related to long-term HIV and hepatitis C infection is a significant cause for
concern as it will cause many deaths among drug users in the future. Indeed, unless there are great
strides forward in treatment, the annual death rate attributable to hepatitis C is likely to eventually
exceed the numbers of deaths caused by overdose at present.
It is therefore vital that interventions to reduce drug-related deaths from long-term causes are prioritised
alongside those intended to reduce deaths from immediate causes.
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Definition
Drug-related death – death where the underlying cause is poisoning, drug abuse or drug dependence
and where any of the substances controlled under the Misuse of Drugs Act (1971) are involved.
This definition has been adopted across the United Kingdom, and is consistent with the information
needs of the European Monitoring Centre for Drugs and Drug Addiction.
Structural issues
Liaison and collaboration
Preventing drug-related deaths is a responsibility that falls across all tiers of drug treatment. It is vital
that the following if the tiered approach set out in Models of Care (NTA 2002) results in effective
integrated care pathways that enable seamless transfer across drug treatment tiers.
Some sectors, in which communication with tier 3 services has often proved problematic in the past,
may benefit from the employment of staff in liaison roles to ensure effective communication and to help
prevent clients ‘falling between services’. This is particularly likely to be so in the cases of accident and
emergency departments and mental health services. 
In whatever way service delivery is configured, there should be clear protocols and guidance on:
• care co-ordination
• assessment, care planning and review
• treatment philosophies and goals
• confidentiality and information sharing.
Arrangements whereby direct referrals can be made between tier 3 drug treatment services and mental
health services, without the need to refer via a general practitioner, are likely to result in more efficient
and timely treatment provision.
Competency and training
The training needs of staff working in drug treatment services should be determined by a training
needs analysis. An organisational training plan should be developed, based on the requirements of the
Drug and Alcohol National Occupational Standards (DANOS 2003), to ensure that, as part of their
continuing professional development, all staff develop the necessary competencies, knowledge and
skills to avert drug-related deaths. All staff conducting assessment procedures should have sufficient
skills and knowledge to conduct ‘tier-appropriate’ risk assessments according to locally agreed
protocols, as outlined in Models of Care (NTA 2002). 
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Agencies should establish the training needs of their organisation by:
• conducting training needs analyses as and when necessary
• developing an organisational training plan that ensures continuing professional development 
for staff and adequate coverage of the particular issues surrounding drug-related deaths
• ‘benchmarking’ staff against the organisational training plan
• where necessary, being reactive to previously unrealised training needs by altering their 
training plans in response to clinical governance mechanisms and the findings of inquiries 
into drug-related deaths. 
Practice issues
Injecting drug use
Injecting is the most hazardous way of taking drugs. It is the main source of both the short- and long-
term risks of drug-related death. 
Therefore, it is important that all services have a clear set of strategies towards injecting drug use. 
These strategies fall under two main headings, as described below.
Reducing injecting drug use 
The main strategies to reduce the numbers of those choosing to inject their drugs are:
• including current injecting drug users (IDUs) who desire it as a priority group for access to 
substitute prescribing, based on the Drug Misuse and Dependence: guidelines on clinical 
management publication (Department of Health 1999). While the evidence base for substitute 
prescribing is clear for those injecting opiates, it is far less so for those injecting stimulants
• publicising the risks of injecting drug use to those at high risk of becoming IDUs and 
advising them of realistic alternatives to injecting
• regularly but sensitively reminding current IDUs of the risks of injecting and offering them 
strategies to move to other routes of administration or to limit the risks of continued use
• using established interventions such as the ‘Break the Cycle’ campaign (DrugScope/Exchange 
2002) with current IDUs, in order to limit their initiation of new injectors.
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Reducing injecting-related harm
This involves providing current IDUs with both the means and opportunity to significantly reduce the
risks associated with injecting. This includes providing easy access to:
• basic assessments, including risk assessments and basic physical health checks, although 
refusal to access such assessments should not be a barrier to provision of equipment
• a comprehensive range of sterile injecting equipment intended for single use (but not 
equipment specifically designed to prevent multiple use, sometimes described as ‘difficult to 
re-use syringes’), including injecting ‘paraphernalia’. Paraphernalia should be supplied in line 
with the recommendations of the Advisory Council on the Misuse of Drugs (2002)
• outlets for injecting equipment, which can include specialist treatment agencies, community 
pharmacies, outreach workers, mobile distribution to specific risk groups such as sex 
workers and, where appropriate, secondary distribution by drug users or others where 
appropriate training, support and supervision can be provided
• a range of disposal facilities for used injecting equipment and regular encouragement to 
dispose of used equipment responsibly. Disposal facilities can be provided via specialist 
needle exchanges, pharmacy needle exchanges and secure ‘bins’ in the community – 
particularly in ‘hotspots’ where used injecting equipment is regularly discarded
• information and advice on avoiding the transmission of blood-borne and other related viruses, 
particularly hepatitis A, B, C and HIV
• blood testing for viral status, particularly for hepatitis C and HIV
• vaccination for hepatitis B, using the protocol(s) most appropriate for the agency (those most 
likely to result in a full course of vaccinations for the client group), and proactively using all 
opportunities for vaccination, including outreach settings where appropriate
• referral for treatment for liver disease and HIV-related diseases
• advice and information on reducing drug-related harm across a range of commonly injected 
drugs, such as heroin, crack cocaine, powder cocaine and amphetamines
• advice and information on avoiding medical complications of injecting, including thromboses, 
emboli, endocarditis, abscesses, ulcers and TB. Treatment or referral to treatment for these 
conditions should also be readily available
• advice and information on specific problems that can result from the injection of amphetamines, 
including the increased likelihood of drug-induced psychosis
• credible and timely information and advice on the avoidance of acute local risks, particularly 
those resulting from bacterial or chemical contamination of street drugs
• advice and information to discourage the injection of unsuitable preparations such 
as tablets
• advice and information on physical health needs.
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Agencies should review the availability of injecting equipment within localities, with a view to ensuring
that geographical coverage is sufficient to meet the needs of local injectors, and increasing equipment
availability in areas where there are gaps in provision. 
Particular regard should be paid to the availability of equipment in areas where cocaine injecting is
known to be prevalent. Agencies should ensure that any limits on the amount of equipment supplied
are realistic, flexible and also meet the greater equipment needs of stimulant injectors when compared
with opiate injectors.
There should be liaison between those distributing injecting equipment and appropriate local bodies to
develop robust written strategies to minimise the likelihood of used injecting equipment being
discarded in the community (by providing widespread access to secure disposal facilities, rather than
by limiting supply of equipment) and to have arrangements for timely and appropriate disposal of
discarded injecting equipment. Arrangements should be flexible to allow for changing patterns of drug
use/drug-using venues and be regularly reviewed for their effectiveness.
Pharmacy needle exchange provision is extremely valuable in both supplying sterile injecting equipment
and collecting used equipment for disposal. However, pharmacy needle exchange alone is very unlikely
to be able to deliver a comprehensive range of interventions for injecting drug users as described in
the bulleted list above.
The use of ‘blue lights’ in places such as public toilets should be actively discouraged. This measure is
intended to reduce injecting in specific venues, by making venous access more difficult to achieve. It is
questionable whether the use of blue lights has any appreciable effect in this objective. However, it is
likely to increase physical harm to individual injectors and where it is effective, displace injecting drug
use to other public areas.
Injecting drug use also carries a very high risk of overdose. Strategies for dealing with overdose are
discussed below.
Overdose
At the time of writing, the majority of acute drug-related deaths are related to opiate overdose and
typically occur in young men under 30 years of age. People who inject heroin are about 14 times more
likely to die than their peers. Almost as many life-years are now lost due to drug-related deaths as the
total from all traffic accidents. Not all overdose deaths will be preventable, but many are. Simple
strategies can have a marked effect on a person’s probability of survival of an accidental overdose. 
Even the number of overdose deaths that occur as a result of deliberate overdose can be reduced by
providing easier access to treatment programmes (where issues of depression or nihilism are more
likely to be recognised and addressed), good assessment of people’s mental health status and better
liaison between drug treatment and mental health services. Treatment services should proactively
screen and provide brief interventions for anxiety and mood disorder, low-level depression and minor
psychopathology. For clients with mental health issues alongside substance use problems, the joint
Alcohol Concern and DrugScope (2002) document, Assessment and Management of Clients with Dual
Diagnosis, lays out the basis of good practice in this area. Models of Care (NTA 2002) gives a clear
framework for the development of auditable assessment tools that are appropriate to localities and to
every level of drug treatment provision. 
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Drug purity levels are commonly believed to be a major cause of overdose deaths, particularly when
there appears to be a ‘spate’ or cluster of deaths. However, purity is seldom a critical factor in causing
death (more often it is to do with the drug-taking behaviour of high-risk groups of drug users in the area
concerned). Messages that talk about ‘very strong’, ‘rogue’ or ‘contaminated’ heroin should therefore
only be given out to drug users and the media where this is based on the evidence of laboratory
analysis. Good practice involves the sharing of relevant and credible information between all agencies.
Messages to drug users should concentrate on specific and credible risks and give clear advice on
how to best avoid or limit them.
Strategies to limit the number of overdose deaths fall under two main headings, as described below.
Preventing overdose
The main strategy to prevent overdose occurring involves the giving of information and advice on the
factors that are most likely to combine to cause an overdose. These include information and advice on
the risks of:
• injecting
• opiate use (including prescribed opiates) alongside other depressant drugs such as alcohol 
or benzodiazepines
• using opiates when tolerance is low, particularly on release from prison, after detoxification 
or after a break in use
• using combinations of heroin and cocaine (known as ‘speedballing’ or ‘snowballing’).
Treatment services should have strategies for maintaining or establishing contact with drug users
leaving prison as they are a high-risk group for overdose.
Recent evidence suggests that detoxification may carry a significant overdose risk for those who are
‘successful’ (in initially achieving abstinence). It is therefore important that:
• detoxification from substitute prescribing is seen as a treatment option with a significant risk 
of mortality that is not normally imposed on service users, but offered as a choice
• the implications of increased mortality risk are fully taken into account if service users are 
involuntarily excluded from substitution treatment
• detoxification programmes are of a realistic length and users are adequately supported 
through them, normally with an open option for users to return to substitute prescribing if
they so wish
• the realities of relapse, including the likelihood of it happening and its attendant risks, are 
regularly discussed with those undertaking detoxification
• adequate support systems exist for those who successfully achieve abstinence – they are a 
group at high risk of overdose death and should therefore not be discharged from contact 
immediately following successful detoxification.
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There are a number of particular risk factors and behaviours that indicate those who are at the highest
risk of overdose death. Staff awareness of these factors and communication of them to those at most
risk may limit the number of overdoses. Risk factors and behaviours include:
• injecting heroin
• recent history of non-fatal overdose
• longer injecting career
• high levels of use or intoxication
• high levels of alcohol use
• low tolerance, or lowered tolerance through detoxification or imprisonment
• depression, feelings of hopelessness and suicidal thoughts
• a history of using combinations of drugs, including benzodiazepines and/or alcohol
• sharing previously used injecting equipment or other high-risk injecting behaviours 
(may be indicative of low concern about personal risk);
• premature exit from a methadone treatment programme
• not being in a methadone or other treatment programme.
It is important in reducing drug-related deaths that effective, evidence-based drug treatment services
are provided. This should include appropriate, well-managed methadone prescribing. Methadone
prescribing services should have an emphasis on providing adequate, evidence-based dose levels and
on engaging and retaining high-risk drug users in treatment. Particular care should be taken in the first
week of methadone treatment, when the risk of overdose is high. 
To prevent diversion of prescribed drugs, particularly to the opiate-naive, measures such as supervised
consumption should be in place for a minimum initial period, in line with Drug Misuse and Dependence:
guidelines on clinical management (Department of Health 1999).
Dealing with overdose
Overdose prevention
The dissemination of messages on overdose prevention and how to react appropriately to an overdose
situation should be an integral part of the routine work of needle exchanges and street agencies.
Ambulance protocols
Overdose incidents should be prioritised as health emergencies and the police should not routinely
attend. Fear of police involvement when an ambulance is called to an overdose incident may inhibit
some drug users from taking this life-saving action. 
All emergency ambulance crews should carry the opiate antagonist naloxone and be trained in how to
use it. Strategies should be explored that encourage overdose victims revived by the use of naloxone to
attend accident and emergency departments, and to remain there until discharged by the department.
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It is important that local protocols are in place that clearly delineate when it is and is not appropriate for
the police to attend overdose incidents. When such protocols are in place, effective communication of
the policy (especially when this represents a change in practice) to drug users is essential. Treatment
services are in an excellent position to communicate this information clearly, unambiguously and
continuously. It is good practice to centrally involve drug user organisations in the development and
communication of such initiatives.
Training courses for drug users
There is often another person – usually a fellow drug user – present when an overdose occurs, and their
actions can be crucial in determining the eventual outcome of the incident. 
Strategies to promote appropriate responses to overdoses include the provision of information and
training courses for drug users, their families and friends on avoiding overdose, and responding
appropriately if it occurs.
The aim of such training courses should be to provide participants with the necessary basic knowledge
and skills to respond effectively, appropriately and confidently to a drugs overdose, and they should
cover the following learning objectives:
• summoning medical assistance appropriately and confidently
• identifying key overdose risks
• recognising the signs and symptoms of overdose
• assessing vital signs and prioritising first-aid actions
• placing someone in the recovery position
• performing mouth-to-mouth resuscitation
• providing cardiopulmonary resuscitation
• awareness of common myths and potentially dangerous practices.
First-aid training should always be provided by qualified personnel. This is usually available from the
local ambulance trust, Red Cross or St John Ambulance.
Stimulants and drug-related death
The number of people known to have died as a result of cocaine-induced heart failure has shown an
increase over recent years. Staff of drug treatment agencies should be competent to offer advice and
information on the particular risks of stimulant use and, where appropriate, how to reduce the risks of
use. Particular areas for discussion should include the risks of:
• using stimulants
• high levels of use
• combined alcohol and cocaine use
• combined opiate and cocaine use
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• stimulant use in hot environments
• the possible increased danger of violent death.
The National Treatment Agency draft document, Treating Crack and Cocaine Misuse: a resource pack
for treatment providers, although presently in draft form and subject to change following pilot testing, 
sets out detailed good practice guidance in commissioning, planning and providing treatment services
for crack and cocaine users, in line with the Drug and Alcohol National Occupational Standards (DANOS
2003), Models of Care (2002) and Quality in Alcohol and Drug Services (QuADS; DrugScope 2000). 
Health problems associated with cocaine and crack
Deaths in custody
Recently published analysis of drug-related deaths in police custody (Havis & Best 2003) indicates that
stimulants generally, and cocaine in particular, are the main drugs associated with overdose deaths in
this setting. Further research is needed in this area, but the possibility is that many such deaths are
associated with some of the following factors:
• swallowing of drug packages at/around the time of arrest – it is likely that many of these 
packages are swallowed in haste, have not been designed to survive passage through the 
body and therefore leak
• concealment of drugs at the time of arrest and later consumption while in custody
• deliberate overdose connected to mental health issues
• a lack of understanding on the part of drug users of the overdose potential of cocaine
• a lack of knowledge and understanding on the part of arresting officers and custody suite 
staff of the potential problems associated with swallowing of stimulants. 
Heart attacks 
Although the known number of deaths from stimulants is relatively small when compared with those in
which opiates are involved, US studies show that up to 25% of heart attacks in people aged between
18 and 45 years are due to cocaine use. The risks of having a possible heart attack are increased by
23 times in the hour after cocaine use. The risks are further increased if alcohol is used as well.
Increased risks of heart attack come from a number of factors, including:
• increased adrenaline (released because of cocaine use)
• high blood pressure (increased heart rate caused by adrenaline)
• constricted blood vessels (cocaine releases a chemical that constricts blood vessels)
• hardening of the arteries (caused by cocaine use)
• weakened heart (congestive heart failure)
• arrhythmias (erratic heartbeat)
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• underlying heart problems
• other drugs that may be used in combination with cocaine, such as alcohol and/or 
Viagra (see below).
Coca-ethylene, a chemical produced in the liver when using cocaine and alcohol together, has a more
damaging effect on the cardiovascular system than if cocaine were taken on its own. Sodium
bicarbonate, used to ‘wash’ cocaine to turn it into crack, also may have a stressful effect on the heart.
Strokes and seizures
Strokes and seizures can also be made more likely by cocaine use. Strokes may be connected to the
constriction of blood vessels and repeated increase in blood pressure from regular use. These
combined factors can sometimes cut off blood flow to parts of the brain (causing seizures/blackouts)
and also in some cases cause delicate blood vessels to break (causing bleeding in the brain).
Lung damage
Taking crack or cocaine can cause many lung problems. These problems are not just isolated to 
smoking crack – injecting crack or cocaine can also cause some of the lung problems listed below. 
Lung problems that are associated with the use of crack or cocaine include:
• pulmonary oedema – build-up of fluid in the lungs
• pulmonary haemorrhage – bleeding in the lungs
• pulmonary barotrauma – air escaping from the lungs into the circulatory system 
(by holding in crack smoke)
• foreign bodies in lungs – poorly designed pipes or no gauze screen used
• ‘crack lung’ – cough, shortness of breath, inflamed lungs, fever.
Other issues
Safe storage of medicines
Accidental poisoning of children who swallow medication prescribed for their parents or carers is
responsible for a number of deaths annually. All clients of services providing take-home opiate
substitution treatment, and particularly those with young children living in their homes, 
should receive:
• advice on the dangers of drugs to young children
• advice on the safe storage of drugs
• their drugs in containers with child-resistant caps
• where possible and appropriate, the provision of lockable safes or containers in which 
to store their drugs.
Community pharmacists are in a good position to provide advice and information on issues of safe storage.
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Tobacco smoking
Many clients of tiers 2 and 3 treatment services are likely to be dependent tobacco smokers, who
would gain significant health benefits from stopping. It is good practice for services to build good
working links with smoking cessation services and, when appropriate to advise their clients of the
health benefits of giving up smoking and offer a referral to the smoking cessation service.
Local information drives
Regular targeted information campaigns can help to increase clients’ awareness of risks and measures
to reduce risk or save lives. Information campaigns should in general:
• focus on the main areas of risk
• be time-limited and change regularly
• only attempt to address one priority issue at a time, rather than having many issues 
competing for attention.
Targeted information campaigns should focus on areas that include:
• hepatitis B transmission and vaccination
• hepatitis C transmission
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